AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AIM ImmunoTech announced that Chris McAleer, Ph.D., and William Mitchell, M.D., Ph.D., will present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care, held from September 8-10, 2022, at Roswell Park Comprehensive Cancer Center, Buffalo, N.Y. The presentations focus on Rintatolimod as an investigational immunomodulatory agent targeting cancers with high unmet need. AIM is sponsoring the event, and details will be available on their website post-presentation.
Details
News Market Reaction – AIM
The recorded move for AIM in the trading session of this news was -4.37%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
OCALA, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced Chris McAleer, Ph.D., Deputy Chief Science Officer of AIM, and William Mitchell, M.D. Ph.D., Chairman of the Board of Directors of AIM, will present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 8-10, 2022. In addition to management’s presentations, the Company is proud to announce its sponsorship of the event.
Presentation Details:
Title: Rintatolimod (Ampligen®): An Investigational Immunomodulatory Agent Targeted at Cancers of High Unmet Need
Author: Christopher McAleer, Ph.D.
Date: Saturday, September 10
Title: The Mechanism of PAMP Restricted Rintatolimod in Limiting Systemic Inflammatory Responses
Author: William M. Mitchell, M.D., Ph.D.
Date: Saturday, September 10
Presentations will take place at the Cancer Genetics & Pharmacology Building at the Roswell Park Comprehensive Center.
For more information about the conference, visit: https://www.roswellpark.org/msc-symposium.
The presentations will be available on the AIM website once presented at the conference.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The Company’s lead product, Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on Twitter, LinkedIn, and Facebook.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.